Partners L P/Ilbiotechnolog... Net Worth

The estimated Net Worth of Partners L P/Ilbiotechnolog... is at least 39.4 百万$ dollars as of 18 February 2014. Partners Ilbiotechnolog owns over 422,900 units of Ligand Pharmaceuticals stock worth over 8,184,315$ and over the last 11 years Partners sold LGND stock worth over 31,214,249$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Ilbiotechnolog LGND stock SEC Form 4 insiders trading

Partners has made over 1 trades of the Ligand Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently Partners sold 422,900 units of LGND stock worth 31,214,249$ on 18 February 2014.

The largest trade Partners's ever made was selling 422,900 units of Ligand Pharmaceuticals stock on 18 February 2014 worth over 31,214,249$. On average, Partners trades about 422,900 units every 0 days since 2014. As of 18 February 2014 Partners still owns at least 79,390 units of Ligand Pharmaceuticals stock.

You can see the complete history of Partners Ilbiotechnolog stock trades at the bottom of the page.

Insiders trading at Ligand Pharmaceuticals

Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over 205,340,014$ worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth 27,601,439$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of 2,239,733$. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth 50,090$.

What does Ligand Pharmaceuticals do?

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.

Complete history of Partners Ilbiotechnolog stock trades at Ligand Pharmaceuticals

Ligand Pharmaceuticals executives and stock owners

Ligand Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Higgins,
  Chief Executive Officer, Director
• Matthew Foehr,
  President, Chief Operating Officer
• Matthew Korenberg,
  Chief Financial Officer, Executive Vice President - Finance
• Charles Berkman,
  Senior Vice President, General Counsel, Secretary
• John L. Higgins,
  CEO & Exec. Director
• Matthew W. Foehr,
  Pres & COO
• Matthew E. Korenberg,
  Exec. VP of Fin. & CFO
• Charles S. Berkman J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Charles S. Berkman,
  Sr. VP, Gen. Counsel & Sec.
• Sarah Boyce,
  Independent Director
• John Kozarich,
  Non-Executive Independent Chairman of the Board
• Stephen Sabba,
  Independent Director
• Jason Aryeh,
  Independent Director
• Todd Davis,
  Independent Director
• Sunil Patel,
  Independent Director
• Nancy Gray,
  Independent Director
• John Lamattina,
  Independent Director
• Simon Latimer,
  Head of Investor Relations
• Patrick Lucy,
  Sr. VP & CBO Protein Expression Bus.
• Dr. Vincent D. Antle,
  Sr. VP of Technical Operations & QA - Capitsol
• Dr. Keith Marschke,
  Sr. VP of Biology & Scientific Affairs
• Audrey Warfield-Graham,
  Sr. VP of HR
• Todd Pettingill,
  Director of Corp. Devel.
• Patrick O'Brien,
  Sr. VP of Investor Relations
• Jason Haas,
  Director
• Corp Plc Elan,
  10% owner
• Andres Negro Vilar,
  Exe V-P, R & D, CSO
• Partners L P/Ilbiotechnolog...,
  
• Bruce Peacock,
  Director
• Zofia E Dziewanowska,
  VP, Clinical Research
• Partners L P/Ilbiotechnolog...,
  
• Melanie J Herman,
  Director of Accounting
• Nishan M De Silva,
  VP, Corporate Development
• David M Knott,
  10% owner
• Syed Kazmi,
  VP, Bus. Dev. & Strategic Plan
• Martin Meglasson,
  V-P, Discovery Research
• Pharmaceuticals Inc Ligand,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Steven J Burakoff,
  Director
• Brigette Roberts,
  Director
• Partners L P/Ilbiotechnolog...,
  
• John P Sharp,
  VP Finance and CFO
• Daniel S Loeb,
  Director
• Michael A Rocca,
  Director
• John Groom,
  Director
• Taylor Crouch,
  Sr. V-P, Ops & Pres. Int'l
• Partners L P/Ilbiotechnolog...,
  
• Jeffrey R Perry,
  Director
• Alexander D Cross,
  Director
• William A Petttit,
  Sr. V-P, HR and Administration
• Paul V Maier,
  Sr. V-P, CFO
• Warner R Broaddus,
  V-P, Gen. Counsel & Secy.
• Elizabeth M Greetham,
  Director
• Henry F Blissenbach,
  Director
• Irving S Johnson,
  Director
• Carl C Peck,
  Director
• Eric S Groves,
  V-P, Project Management
• Giambattista Aliprandi,
  Sr. VP, Tech., Sup & Intl Oper
• James J Litalien,
  Sr. V-P, Reg Affairs & Comp.
• David E Robinson,
  President & CEO
• Tod Mertes,
  V-P, Controller & Treasurer
• Jennifer R. Cochran,
  
• Octavio Espinoza,
  Chief Financial Officer
• Martine Zimmermann,
  Director
• Andrew Reardon,
  CLO & Secretary